Joel B. Nelson
University of Pittsburgh · 496 works · 22,408 citations · h-index 60
Top works
- Comprehensive molecular characterization of clear cell renal cell carcinoma
- The Molecular Taxonomy of Primary Prostate Cancer
- A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
- Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy
- Laparoscopic nephrectomy for renal cell cancer: evaluation of efficacy and safety: a multicenter experience
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
- Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate
- Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options
- Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer
- Grading Nephroureteral Dilatation Detected in the First Year of Life: Correlation with Obstruction
- Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial
- The endothelin axis: emerging role in cancer
- Transcriptional programs activated by exposure of human prostate cancer cells to androgen
- Increased fatty acid synthase as a therapeutic target in androgen‐independent prostate cancer progression
- Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
- Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer
- Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
- Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer
- A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer